Strategic Capital Advisers Inc. acquired a new stake in shares of Stryker Co. (NYSE:SYK) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 16,607 shares of the medical technology company’s stock, valued at approximately $2,571,000. Stryker accounts for 2.5% of Strategic Capital Advisers Inc.’s portfolio, making the stock its 9th biggest position.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Raymond James Financial Services Advisors Inc. grew its position in Stryker by 4.5% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 172,329 shares of the medical technology company’s stock worth $24,474,000 after purchasing an additional 7,499 shares in the last quarter. Victory Capital Management Inc. grew its position in Stryker by 21.2% during the 3rd quarter. Victory Capital Management Inc. now owns 24,114 shares of the medical technology company’s stock worth $3,425,000 after purchasing an additional 4,222 shares in the last quarter. Dupont Capital Management Corp purchased a new position in Stryker during the 3rd quarter worth approximately $274,000. Empirical Finance LLC purchased a new position in Stryker during the 3rd quarter worth approximately $210,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in Stryker by 4.2% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 55,051 shares of the medical technology company’s stock worth $7,818,000 after purchasing an additional 2,219 shares in the last quarter. Institutional investors and hedge funds own 75.71% of the company’s stock.
In related news, VP William E. Berry, Jr. sold 1,306 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $164.42, for a total value of $214,732.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Graham A. Mclean sold 2,984 shares of the stock in a transaction on Monday, February 5th. The shares were sold at an average price of $160.53, for a total transaction of $479,021.52. Following the completion of the sale, the insider now owns 9,100 shares of the company’s stock, valued at approximately $1,460,823. The disclosure for this sale can be found here. Insiders have sold 43,611 shares of company stock valued at $7,178,719 in the last three months. 7.40% of the stock is owned by insiders.
A number of equities research analysts have issued reports on the stock. Needham & Company LLC reissued a “hold” rating on shares of Stryker in a research note on Wednesday, January 31st. Citigroup raised shares of Stryker from a “sell” rating to a “neutral” rating and lifted their target price for the company from $165.77 to $166.00 in a research note on Tuesday, February 27th. ValuEngine raised shares of Stryker from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. Piper Jaffray Companies lifted their target price on shares of Stryker from $156.00 to $166.00 and gave the company an “overweight” rating in a research note on Tuesday, January 9th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and issued a $163.00 price objective on shares of Stryker in a research note on Tuesday, January 30th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and fifteen have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $163.85.
Shares of Stryker Co. (NYSE SYK) traded down $0.73 during midday trading on Wednesday, reaching $166.38. 736,549 shares of the company traded hands, compared to its average volume of 1,480,000. Stryker Co. has a fifty-two week low of $129.82 and a fifty-two week high of $170.00. The firm has a market capitalization of $62,330.00, a price-to-earnings ratio of 33.96, a P/E/G ratio of 2.41 and a beta of 0.70. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.29 and a quick ratio of 1.59.
Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.95 by $0.01. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The business had revenue of $3.47 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period in the prior year, the business posted $1.78 earnings per share. Stryker’s revenue was up 9.9% compared to the same quarter last year. equities research analysts anticipate that Stryker Co. will post 7.12 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 1.13%. The ex-dividend date of this dividend is Wednesday, March 28th. Stryker’s dividend payout ratio is 38.37%.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.